Indaptus Therapeutics (INDP) Competitors $0.48 -0.01 (-1.66%) Closing price 04/17/2025 03:19 PM EasternExtended Trading$0.49 +0.01 (+2.74%) As of 04/17/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INDP vs. PLUR, ALXO, VYNE, GDTC, CLNN, DARE, CASI, CARA, QTTB, and GBIOShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Pluri (PLUR), ALX Oncology (ALXO), VYNE Therapeutics (VYNE), CytoMed Therapeutics (GDTC), Clene (CLNN), Daré Bioscience (DARE), CASI Pharmaceuticals (CASI), Cara Therapeutics (CARA), Q32 Bio (QTTB), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Pluri ALX Oncology VYNE Therapeutics CytoMed Therapeutics Clene Daré Bioscience CASI Pharmaceuticals Cara Therapeutics Q32 Bio Generation Bio Indaptus Therapeutics (NASDAQ:INDP) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership. Does the media prefer INDP or PLUR? In the previous week, Pluri had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 2 mentions for Pluri and 1 mentions for Indaptus Therapeutics. Pluri's average media sentiment score of 0.74 beat Indaptus Therapeutics' score of -1.00 indicating that Pluri is being referred to more favorably in the news media. Company Overall Sentiment Indaptus Therapeutics Negative Pluri Positive Do analysts recommend INDP or PLUR? Indaptus Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 1,689.47%. Given Indaptus Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Indaptus Therapeutics is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Pluri 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor INDP or PLUR? Indaptus Therapeutics received 13 more outperform votes than Pluri when rated by MarketBeat users. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%PluriN/AN/A Do insiders & institutionals believe in INDP or PLUR? 7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 29.5% of Indaptus Therapeutics shares are held by insiders. Comparatively, 10.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better earnings & valuation, INDP or PLUR? Indaptus Therapeutics has higher earnings, but lower revenue than Pluri. Pluri is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.62-0.29Pluri$678K40.51-$20.89M-$5.60-0.70 Which has more risk and volatility, INDP or PLUR? Indaptus Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Is INDP or PLUR more profitable? Indaptus Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Indaptus Therapeutics' return on equity of -177.27% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% Pluri -3,551.49%-2,778.13%-83.61% SummaryIndaptus Therapeutics beats Pluri on 10 of the 16 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.85M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.29%P/E Ratio-0.286.9521.9417.81Price / SalesN/A231.03380.9597.68Price / CashN/A65.6738.2634.64Price / Book0.335.936.453.98Net Income-$15.42M$143.22M$3.22B$247.81M1 Month Performance-38.35%-13.56%-9.76%-7.91%1 Year Performance-79.87%-8.89%11.49%1.53% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.4689 of 5 stars$0.48-1.7%$8.50+1,689.5%-79.9%$6.85MN/A-0.286Short Interest ↑Negative NewsGap UpPLURPluri0.8831 of 5 stars$3.89+1.8%N/A-25.2%$27.22M$678,000.00-0.69150Short Interest ↓News CoverageALXOALX Oncology3.0237 of 5 stars$0.50+2.3%$4.14+725.9%-96.5%$26.76MN/A-0.1740VYNEVYNE Therapeutics2.9013 of 5 stars$1.75+12.5%$6.88+292.9%-17.8%$26.62M$501,000.00-2.0330High Trading VolumeGDTCCytoMed Therapeutics2.0575 of 5 stars$2.43-2.0%$5.00+105.8%+17.1%$26.58MN/A0.00N/APositive NewsCLNNClene2.6696 of 5 stars$3.08+1.7%$55.25+1,693.8%-57.0%$26.05M$342,000.00-0.58100Short Interest ↑Gap UpDAREDaré Bioscience1.9121 of 5 stars$2.93-0.3%$24.00+719.1%-13.7%$25.93M$9,784.00-4.9630Short Interest ↓News CoverageCASICASI Pharmaceuticals4.1374 of 5 stars$2.10+7.6%$4.00+90.7%-10.2%$25.80M$28.54M-0.94180Analyst ForecastShort Interest ↓Gap UpCARACara Therapeutics3.5483 of 5 stars$5.55+13.3%$27.84+401.6%N/A$25.39M$7.14M-0.2680Stock SplitGap DownQTTBQ32 Bio1.7926 of 5 stars$1.92-7.7%$24.71+1,187.2%-90.6%$25.37M$-6,651,000.00-0.1339News CoverageGBIOGeneration Bio2.7692 of 5 stars$0.37-3.4%$7.33+1,860.8%-86.1%$25.06M$19.89M-0.17150High Trading Volume Related Companies and Tools Related Companies PLUR Alternatives ALXO Alternatives VYNE Alternatives GDTC Alternatives CLNN Alternatives DARE Alternatives CASI Alternatives CARA Alternatives QTTB Alternatives GBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INDP Stock Free INDP Stock Alerts